Literature DB >> 12093693

Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Seon-Hee Cheon1, Beate Kampmann, Amy G Hise, Manijeh Phillips, Ho-Yeon Song, Katherine Landen, Qing Li, Rhonda Larkin, Jerrold J Ellner, Richard F Silver, Daniel F Hoft, Robert S Wallis.   

Abstract

The development of new tuberculosis (TB) vaccines will require the identification of correlates of human protection. This study examined the balance between immunity and virulence in a whole blood infection model in which intracellular mycobacterial survival was measured using BACTEC. In the blood of tuberculin-negative donors, counts of Mycobacterium tuberculosis H(37)Ra organisms fell by 0.14 log(10) CFU during 96 h of whole blood culture, whereas counts of Mycobacterium bovis BCG, M. tuberculosis H(37)Rv, and a clinical TB isolate's organisms increased by 0.13, 0.43, and 1.04 log(10) CFU, respectively (P < 0.001), consistent with their relative virulence. Inhibition of tumor necrosis factor alpha by the addition of methylprednisolone or pentoxifylline or removal of CD4(+) or CD8(+) T cells by magnetic beads had deleterious effects on immune control of intracellular growth only in the blood of tuberculin-positive donors. Repeated vaccination of eight tuberculin-negative volunteers with M. bovis BCG resulted in a 0.3 log (50%) reduction in BCG CFU counts in the model compared to baseline values (P < 0.05). Three of the volunteers responded only after the second vaccination. These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093693      PMCID: PMC120034          DOI: 10.1128/cdli.9.4.901-907.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Propelling novel vaccines directed against tuberculosis through the regulatory process.

Authors:  M J Brennan; F M Collins; S L Morris
Journal:  Tuber Lung Dis       Date:  1999

3.  Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis.

Authors:  R Hussain; H Shiratsuchi; M Phillips; J Ellner; R S Wallis
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

4.  Vaccine protocols to optimise the protective efficacy of BCG.

Authors:  J F Griffin; C G Mackintosh; L Slobbe; A J Thomson; G S Buchan
Journal:  Tuber Lung Dis       Date:  1999

5.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

6.  A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival.

Authors:  R Teitelbaum; A Glatman-Freedman; B Chen; J B Robbins; E Unanue; A Casadevall; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

7.  Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions.

Authors:  R F Silver; Q Li; J J Ellner
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

Review 8.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

9.  Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects.

Authors:  R F Silver; Q Li; W H Boom; J J Ellner
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

10.  Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity.

Authors:  R J North; A A Izzo
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  38 in total

1.  Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Authors:  Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity.

Authors:  Ernestas Janulionis; Carolina Sofer; Stephan K Schwander; Denarra Nevels; Barry Kreiswirth; Elena Shashkina; Robert S Wallis
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans.

Authors:  Mangalakumari Jeyanathan; Daniela Damjanovic; Yushi Yao; Jonathan Bramson; Fiona Smaill; Zhou Xing
Journal:  J Infect Dis       Date:  2016-10-04       Impact factor: 5.226

5.  Novel human in vitro system for evaluating antimycobacterial vaccines.

Authors:  Beate Kampmann; Gwen N Tena; Shumikazi Mzazi; Brian Eley; Douglas B Young; Michael Levin
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Assessment of in vitro immunity to Mycobacterium tuberculosis in a human peripheral blood infection model using a luciferase reporter construct of M. tuberculosis H37Rv.

Authors:  R Al-Attiyah; A El-Shazly; A S Mustafa
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

7.  Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture.

Authors:  Ernestas Janulionis; Carolina Sofer; Ho-Yeon Song; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis.

Authors:  Marcela Parra; Amy L Yang; JaeHyun Lim; Kristopher Kolibab; Steven Derrick; Nathalie Cadieux; Liyanage P Perera; William R Jacobs; Michael Brennan; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2009-05-20

9.  Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.

Authors:  Robert S Wallis; Solange Vinhas; Ernestas Janulionis
Journal:  Tuberculosis (Edinb)       Date:  2009-03-24       Impact factor: 3.131

10.  Development of vaccines to control the worldwide tuberculosis pandemic.

Authors:  Daniel F Hoft
Journal:  Mo Med       Date:  2014 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.